Answers are grounded in this paper and cite their sources.
ONCOLOGY sat down with Sagar Lonial, MD, professor and chair of Hematology and Medical Oncology at the Emory University School of Medicine and chief medical officer at Emory's Winship Cancer Institute, to discuss the FDA approval of the antibody-drug conjugate belantamab mafodotin, along with other BCMA-targeting agents for patients with multiple myeloma.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: